- Home
- PBA vs WAT Comparison
PBA vs WAT Comparison
Compare PBA & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- WAT
- Stock Information
- Founded
- PBA 1997
- WAT 1958
- Country
- PBA Canada
- WAT United States
- Employees
- PBA N/A
- WAT N/A
- Industry
- PBA Oil & Gas Production
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- PBA Energy
- WAT Industrials
- Exchange
- PBA Nasdaq
- WAT Nasdaq
- Market Cap
- PBA 21.6B
- WAT 17.8B
- IPO Year
- PBA N/A
- WAT 1995
- Fundamental
- Price
- PBA $39.82
- WAT $306.63
- Analyst Decision
- PBA
- WAT Hold
- Analyst Count
- PBA 0
- WAT 14
- Target Price
- PBA N/A
- WAT $374.07
- AVG Volume (30 Days)
- PBA 1.5M
- WAT 603.2K
- Earning Date
- PBA 11-04-2025
- WAT 10-31-2025
- Dividend Yield
- PBA 5.02%
- WAT N/A
- EPS Growth
- PBA N/A
- WAT 10.77
- EPS
- PBA 2.18
- WAT 11.09
- Revenue
- PBA $5,911,897,112.00
- WAT $3,046,056,000.00
- Revenue This Year
- PBA $10.93
- WAT $7.15
- Revenue Next Year
- PBA $7.81
- WAT $6.34
- P/E Ratio
- PBA $18.29
- WAT $27.68
- Revenue Growth
- PBA 20.59
- WAT 5.89
- 52 Week Low
- PBA $34.13
- WAT $275.05
- 52 Week High
- PBA $43.44
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- PBA 70.67
- WAT 55.20
- Support Level
- PBA $38.32
- WAT $294.96
- Resistance Level
- PBA $39.33
- WAT $311.44
- Average True Range (ATR)
- PBA 0.54
- WAT 9.19
- MACD
- PBA 0.16
- WAT 1.02
- Stochastic Oscillator
- PBA 98.30
- WAT 80.99
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.